We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -52.00 | -0.42% | 12,318.00 | 12,290.00 | 12,292.00 | 12,428.00 | 12,260.00 | 12,326.00 | 4,007,480 | 16:35:03 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 32.00 | 190.55B |
From May 2022 to May 2024
By Joe Hoppe
AstraZeneca PLC said Thursday that a Phase 3 trial showed that its Imfinzi product significantly improved event-free survival in patients with resectable non-small cell lung cancer.
The Anglo-Swedish pharma major said the positive high-level results from an interim analysis of the AEGEAN trial showed treatment using Imfinzi coupled with chemotherapy before surgery and monotherapy showed statistically significant and clinically meaningful improvement in the time patients live without recurrence or progression events.
The drug was well-tolerated and no new safety concerns were observed. It didn't increase complications or adverse events nor compromised patients' abilities to undergo surgery when compared with chemotherapy alone.
The company said separately that its Tagrisso cancer drug's first Phase 3 trial showed a statistically significant and clinically meaningful improvement in overall survival in treating patients with early-stage non-small cell lung cancer after tumor resection when compared with placebo.
Tagrisso's safety and tolerability was also consistent with its established profile and no new safety concerns were reported.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
March 09, 2023 03:14 ET (08:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
